(NYSE: JNJ) Johnson & Johnson's forecast annual revenue growth rate of 4.61% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.76%.
Johnson & Johnson's revenue in 2024 is $81,796,000,000.On average, 6 Wall Street analysts forecast JNJ's revenue for 2024 to be $212,464,774,178,215, with the lowest JNJ revenue forecast at $212,030,842,701,483, and the highest JNJ revenue forecast at $213,012,767,808,147. On average, 6 Wall Street analysts forecast JNJ's revenue for 2025 to be $217,726,431,895,670, with the lowest JNJ revenue forecast at $216,340,579,381,648, and the highest JNJ revenue forecast at $218,875,438,297,935.
In 2026, JNJ is forecast to generate $225,901,162,976,379 in revenue, with the lowest revenue forecast at $223,183,394,035,505 and the highest revenue forecast at $228,851,123,511,470.